Bristol-Myers Squibb Company (BMY)
| Market Cap | 124.30B +40.0% |
| Revenue (ttm) | 49.19B +3.1% |
| Net Income | 9.28B +83.8% |
| EPS | 4.54 +82.7% |
| Shares Out | 2.04B |
| PE Ratio | 13.37 |
| Forward PE | 9.95 |
| Dividend | $2.52 (4.14%) |
| Ex-Dividend Date | Oct 2, 2026 |
| Volume | 2,404,764 |
| Open | 61.50 |
| Previous Close | 61.68 |
| Day's Range | 60.72 - 61.81 |
| 52-Week Range | 42.52 - 68.64 |
| Beta | 0.18 |
| Analysts | Hold |
| Price Target | 65.63 (+7.86%) |
| Earnings Date | Oct 29, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $65.63, which is an increase of 7.86% from the latest price.
News
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026.
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.
Bristol Phase 3 win underscores opportunity for GRI Bio, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating and $10 price target on GRI Bio (GRI) after Bristol Myers Squibb (BMY) reported data from its Phase 3 ALOFT-IPF trial of admilparant in…
Bristol Myers price target lowered to $60 from $65 at Wells Fargo
Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal Weight rating on the shares. The firm sees…
Bristol Myers price target raised to $76 from $73 at Jefferies
Jefferies analyst Akash Tewari raised the firm’s price target on Bristol Myers (BMY) to $76 from $73 and keeps a Buy rating on the shares after the company reported “positive”…
RBC says Bristol Myers’ ALOFT-IPF efficacy ‘encouraging, but confounding’
After Bristol Myers (BMY) announced positive topline results from both the Phase 3 ALOFT-IPF trial for admilparant in IPF and the ACTION-1 trial for RYZ101 in GEP-NETs, RBC Capital analyst…
Bristol Myers has blockbuster opportunity in IPF, says William Blair
William Blair keeps a Market Perform rating on Bristol Myers (BMY) after the company announced results from its Phase III study of admilparant in idiopathic pulmonary fibrosis. The trial met…
Bristol Myers tells Bloomberg admilparent death unlikely due to drug
Bristol Myers (BMY) told Bloomberg says the patient death in the admilparant’s study was unlikely due to the drug. The idiopathic pulmonary fibrosis patient was getting the higher dose of…
Bristol Phase 3 success with admilparant should send Contineum up, says Stifel
After Bristol Myers Squibb (BMY) announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant in adults with idiopathic pulmonary ...
Bristol Myers reports ‘positive’ interim analysis of ACTION-1 trial by RayzeBio
Bristol Myers (BMY) Squibb announced positive topline results from the planned interim analysis of the ACTION-1 trial conducted by RayzeBio, a Bristol Myers Squibb company. The study met the primary…
Bristol Myers says Phase 3 ALOFT-IPF trial of admilparant met primary endpoint
Bristol Myers (BMY) Squibb announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally admini...
Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial
Bristol Myers Squibb said on Monday a lower dose of its experimental drug slowed the progression of a serious lung-scarring disease, putting it on track to be a first-of-its-kind treatment if approv...
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACTION--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101.
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ALOFT--Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint.
Bristol Myers price target lowered to $66 from $71 at BofA
BofA lowered the firm’s price target on Bristol Myers (BMY) to $66 from $71 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview…
Bristol Myers price target lowered to $53 from $59 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Bristol Myers (BMY) to $53 from $59 and keeps a Neutral rating on the shares. Near-term earnings remain driven…
Bristol Myers’ zenbexus in combination shows efficacy in Phase 3 myeloma trial
Bristol Myers (BMY) announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating zenbexus – iberdomide – in combination with daratumumab and dexamethasone – ZDd – in 800 patien...
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Myeloma--Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior.
Bristol Myers price target raised to $41 from $40 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $41 from $40 and keeps an Underweight rating on the shares. The firm adjusted its…
Leerink downgrades Bristol Myers to Market Perform, lowers target to $59
As previously reported, Leerink downgraded Bristol Myers (BMY) to Market Perform from Outperform with a price target of $59, down from $73. The firm changed its investment thesis after conducting…
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement.
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. FDA Approves Expanded Indication for BMS's CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients.
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #IMS26--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial.